< >


PRAGMA Therapeutics is a French biotech company, dedicated to the discovery and development of novel treatments for stress related disorders, in particular for Post-Traumatic Stress Disorders, and hearing loss. Founded in 2015, PRAGMA is a flexible organization led by an experienced team of international neuroscience leaders, and developing proprietary small molecules that normalize glutamate functions.

Targeting mGlu7 receptor for PTSD and HEARING LOSS

Post-Traumatic Stress Disorder is a psychiatric disorder which can develop following exposure to a traumatic event (e.g., combat exposure, terrorist attack, car crash), and is characterized by altered fear-related learning and extinction related to glutamate dysfunction in trauma-related brain regions. Hearing Loss may develop slowly over many years or set in acutely (e.g. following some noise or head trauma). It may be either due to insufficient sound conduction from the outer to the inner ear or much more frequently to damage to the hair cells and neurons in the cochlea or to the auditory nerve. PRAGMA Therapeutics develops innovative medicines through modulation of the metabotropic glutamate receptor subtype 7 (mGlu7) for the treatment of these two severe debilitating conditions affecting both civilian and military populations.



September 1, 2016 - PRAGMA Therapeutics has signed a major collaboration with the Center for Defence Enterprise, a division of the Defence Science and Technology Laboratory from the UK Ministry of Defence to support preclinical research on innovative treatments for tinnitus.

June 20, 2016 - PRAGMA Therapeutics receives the Tremplin Entreprises 2016 award.

May 26, 2016 - PRAGMA Therapeutics wins the 2016 Innovation Award from MassChallenge Switzerland.

April 25, 2016 - PRAGMA Therapeutics awarded first prize and £300,000 from UK charity Action on Hearing Loss to develop new drugs to treat Hearing Loss.

More news and events...